Nanexa and Novo enter into EUR 1.165 billion global license and collaboration agreement for long-acting injectables
Why now
Thesis: Novo deepens obesity and diabetes delivery tech
Catalyst to watch: Clinical milestones for PharmaShell candidates
Main risk: Milestone payments and development failure
Why it matters
A EUR 1.165bn licensing deal expands Novo's long-acting injectable pipeline in obesity and diabetes.
Details
The agreement grants Novo a global exclusive license to Nanexa's proprietary PharmaShell® atomic layer deposition (ALD) drug delivery technology platform for certain therapeutic peptide drugs in indications including obesity, type 2 diabetes and other cardiometabolic diseases. The...
Related assets & topics
HealthcareSources
- prnewswire · 2026-09-25 12:00 UTC